NTRP - Neurotrope, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.2800
-0.0400 (-0.93%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.3200
Open4.3000
Bid4.14 x 1200
Ask4.60 x 800
Day's Range4.0600 - 4.3000
52 Week Range3.3300 - 11.9260
Volume54,472
Avg. Volume42,432
Market Cap55.308M
Beta (3Y Monthly)3.01
PE Ratio (TTM)N/A
EPS (TTM)-1.47
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.50
Trade prices are not sourced from all markets
  • Biotech company offering Alzheimer’s disease patients hope with new drug
    Yahoo Finance Video2 months ago

    Biotech company offering Alzheimer’s disease patients hope with new drug

    Alzheimer’s disease affects some 5.7 million Americans, but biotech company Neurotrope is offering patients new hope with a drug it says shows a “reversal” in the disease. Yahoo Finance’s Alexis Christoforous speaks to Neurotrope CEO Dr. Charles Ryan about his company’s findings.

  • PR Newswire13 days ago

    Neurotrope to Participate in the BIO CEO & Investor Conference

    NEW YORK, Feb. 8, 2019 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Charles Ryan, J.D., Ph.D., Neurotrope's Chief Executive Officer, will be participating in an educational panel entitled, "Attacking Biological Mechanisms of Aging to Extend Healthspan" at the BIO CEO & Investor Conference in New York on Monday, February 11th, 2019 at 3:30 p.m. Eastern Time. Neurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases. The Company's world-class science offers the potential to realize a paradigm shift to overcome one of today's most challenging clinical problems — finding a way to slow or even prevent the progression of AD.

  • PR Newswire17 days ago

    Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute

    NEW YORK, Feb. 4, 2019 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the research and clinical development of Bryostatin-1.

  • PR Newswire2 months ago

    Neurotrope to Participate in the Sachs Associates 2nd Annual Neuroscience Innovation Forum

    NEW YORK, Jan. 3, 2019 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Daniel Alkon, M.D., Neurotrope's President and Chief Scientific Officer, will be participating in a panel discussion entitled "Progress in Alzheimer's" at the Sachs Associates 2nd Annual Neuroscience Innovation Forum in San Francisco on Sunday, January 6th, 2019 at 10:25 a.m. Pacific Time. Neurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases. The Company's world-class science offers the potential to realize a paradigm shift to overcome one of today's most challenging clinical problems — finding a way to slow or even prevent the progression of AD.

  • PR Newswire2 months ago

    Neurotrope Announces the Appointment of Two New Board Members

    Dr. Ivan Gergel Brings Clinical Expertise and Product Development Leadership Resulting in Industry-Leading Product Launches Including Namenda® for Alzheimer's Disease Jonathan Schechter Brings Deep Financial ...

  • PR Newswire2 months ago

    Neurotrope Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease in the Journal of Alzheimer's Disease

    NEW YORK, Dec. 17, 2018 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that data from its Phase 2, multidose, exploratory trial evaluating Bryostatin-1 as a treatment of cognitive deficits in moderate to severe Alzheimer's disease were published online in the Journal of Alzheimer's Disease. The double-blind, placebo-controlled, Phase 2 trial, which was completed in May 2017, randomized patients 1:1:1 into 20 μg Bryostatin-1, 40 μg Bryostatin-1, and placebo arms.

  • PR Newswire2 months ago

    Neurotrope Announces $22.5 Million Registered Direct Offering

    NEW YORK, Dec. 17, 2018 /PRNewswire/ -- Neurotrope, Inc. (NTRP) today announced the pricing of a registered direct offering of 5,012,677 shares of common stock and warrants to purchase up to an aggregate of 5,012,677 shares of common stock to institutional and other accredited investors.  Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined purchase price of $4.495, resulting in gross proceeds of approximately $22.5 million. The shares of common stock and the warrants will be immediately separable and will be issued separately. A final prospectus supplement related to the offering will be filed with the SEC, and will be available on the SEC's website located at http://www.sec.gov and may also be obtained from GP Nurmenkari Inc., 22 Elizabeth Street Sono Square, Suite 1J, Norwalk, CT 06854 or by calling (212) 447-5550.

  • Neurotrope Presents Updated Phase 2 Data of Bryostatin-1 in Moderate to Severe Alzheimer's Disease at the 11th Edition of CTAD
    PR Newswire4 months ago

    Neurotrope Presents Updated Phase 2 Data of Bryostatin-1 in Moderate to Severe Alzheimer's Disease at the 11th Edition of CTAD

    NEW YORK, Oct. 24, 2018 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced the presentation of updated data from the Phase 2, multidose, exploratory trial evaluating Bryostatin-1 as a treatment of cognitive deficits in moderate to severe Alzheimer's disease ("AD"). The data were presented in a poster, entitled "Evidence of Sustained Low Dose Bryostatin Efficacy for Treatment of Alzheimer's Disease: Consistency of Multiple Evaluation Analyses" at the 11th Edition of Clinical Trials on Alzheimer's Disease ("CTAD") being held in Barcelona, Spain from October 24th - 27th, 2018. "We are encouraged by the findings of this exploratory trial as we believe they are suggestive of the primary mechanisms of action of bryostatin, synaptogenesis and anti-apoptosis, or the generation of new, mature synaptic connections and the prevention of neuronal death," stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope.

  • PR Newswire5 months ago

    Neurotrope to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    NEW YORK, Sept. 27, 2018 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced that Dr. Charles Ryan, Neurotrope's Chief Executive Officer, will present a company overview at the Ladenburg Thalmann 2018 Healthcare Conference in New York on Tuesday, October 2nd, 2018 at 9:30 a.m. Eastern Time. A live webcast of the presentation will be available on the "Events and Presentations" page in the "Investors and Media" section of the Company's website at http://www.neurotrope.com/. The presentation will be archived on the Company's website and be available for replay for 90 days.

  • PR Newswire5 months ago

    Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer's Disease (CTAD2018)

    NEW YORK, Sept. 26, 2018 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced that updated data on its lead compound, bryostatin, will be presented during the 11th Edition of Clinical Trials on Alzheimer's Disease to be held in Barcelona, Spain from October 24th - 27th, 2018. "Leveraging decades of work on the PKC pathway at NIH and other leading institutions, bryostatin uses a novel mechanism of action to generate new, mature synaptic connections and prevent neuronal death in Alzheimer's disease models," said Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope. "We are highly encouraged by the translation of this work to the clinic, with results from our Phase 2 study in Alzheimer's disease showing promising early signals of clinical improvement in moderate to severe AD patients, a population largely neglected in drug development.

  • PR Newswire6 months ago

    Neurotrope Enters into Collaboration with the Nemours / Alfred I. duPont Hospital for Children to Initiate a Clinical Trial in Fragile X Syndrome

    NEW YORK, Sept. 5, 2018 /PRNewswire/ -- Neurotrope Inc. (NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease (AD), is announcing a collaboration with The Nemours / Alfred I. duPont Hospital for Children ("Nemours") to initiate a clinical trial in children with Fragile X Syndrome ("Fragile X").  The planned protocol for the pilot open-label trial will dose Fragile X patients from 8 to less than 18 years of age, using a dosing regimen similar to that being tested in AD patients. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior.   "We are delighted to be collaborating with clinical scientists at Nemours on this important study for Fragile X.  As one of the premier children's hospitals in the United States, this hospital has both the patient population and the clinical team required to execute this study," stated Dr. Charles Ryan, Chief Executive Officer of Neurotrope.

  • Neurotrope Sees Hammer Chart Pattern: Time to Buy?
    Zacks6 months ago

    Neurotrope Sees Hammer Chart Pattern: Time to Buy?

    Neurotrope, Inc. (NTRP) has been struggling lately, but the selling pressure may be coming to an end soon.

  • PR Newswire6 months ago

    Neurotrope Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018

    The Company has also been selected to present at the prestigious 25th Annual NewsMakers in the Biotech Industry on Friday, September 7th, 8:30am Eastern Time, at the Millennium Broadway Hotel and Conference Center in New York.  This presentation will not be available for webcast. Drs. Charles Ryan, and Daniel Alkon, Neurotrope's CEO and President / CSO, will provide an overview of the Company's business plan and technology during their live presentations and they will also be available to participate in one-on-one meetings throughout the days with investors who are registered to attend the conferences.

  • PR Newswire6 months ago

    Neurotrope Provides Business Update and Reports Second Quarter 2018 Financial Results

    NEW YORK, Aug. 13, 2018 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today provided a business update outlining recent clinical development progress and other noteworthy events that occurred subsequent to the end of the quarter and unaudited financial results for the quarter ended June 30, 2018. On July 17, 2018, Neurotrope announced that it initiated enrollment of a confirmatory Phase 2 clinical trial in 100 moderate to severe AD (defined as a Mini Mental State Exam 2 score of 4-15). Patients will be randomized 1:1 to be treated with either Bryostatin-1 20ug, or placebo, receiving 7 doses over 12 weeks. Dosing has begun in the study, and we are anticipating completion of the study sometime during the third quarter of 2019. The study will be conducted at approximately 30 clinical trial sites.

  • PR Newswire7 months ago

    At AAIC 2018, Neurotrope Presents Additional Clinical Results Showing Cognitive Improvement in Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients

    NEW YORK, July 25, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) today presented additional clinical results from its recently completed Phase 2 trial demonstrating that moderate-to-severe Alzheimer's disease (AD) patients treated with 20 µg Bryostatin-1 showed evidence of sustained improvement in cognition compared with placebo in patients not on concomitant memantine treatment, with a safety profile similar to placebo. The data and comprehensive statistical analysis are being presented in the Developing Topics Poster Presentation, "Significant Cognitive Improvement with Bryostatin for Advanced Alzheimer's Patients in the Absence of Memantine" at the Alzheimer's Association International Conference 2018 in Chicago.

  • Benzinga7 months ago

    Neurotrope Returns After 'Failed' Alzheimer's Trial, But Has Anything Changed?

    Neurotrope Inc (NASDAQ: NTRP) announced Monday that it has initiated enrollment for a confirmatory Phase 2 study of bryostatin-1 in Alzheimer’s disease. The typically good news of a drug candidate's progress may not be enough to clear the public's memory of Neurotrope. In early 2017, Neurotrope popped nearly 250 percent after early expectations for bryostatin suggested leadership in Alzheimer’s research.

  • PR Newswire7 months ago

    Neurotrope Announces the Initiation of Enrollment of its Confirmatory Phase 2 Trial in Alzheimer's Disease

    NEW YORK, July 16, 2018 /PRNewswire/ -- Neurotrope Inc. (NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), is announcing that the first patient has been enrolled into its confirmatory Phase 2 clinical trial with its lead Alzheimer's disease drug, Bryostatin-1.  Patient recruitment will take place at approximately 30 clinical sites in the United States. "The potentially important persistence of the bryostatin-induced improvement in the SIB scores in our recently completed Phase 2 trial, even one month after completion of all dosing, is an effect that we hope to repeat in this confirmatory trial.  Immunologic A Beta degradation has recently been the target of Biogen trials that appear to reduce the rate of cognitive decline in prodromal and early AD patients.  Bryostatin's mechanism also contributes to the elimination of A Beta oligomers and amyloid plaques through activation of brain A Beta degradation enzymes.  In addition, we believe the persistent reversal of cognitive decline in advanced AD patients may result from the multi-modal efficacies of bryostatin that include growth of new synapses and prevention of neuronal death.   In late-stage AD patients in our Phase 2 trial, bryostatin appeared to cause an increase in cognition – i.e.

  • PR Newswire7 months ago

    Neurotrope Appoints Leading Experts in Alzheimer's Disease to its Scientific Advisory Board (SAB)

    NEW YORK, July 11, 2018 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), is announcing that it has established its Scientific Advisory Board (SAB) comprised of experts in the fields of AD and other Neurological diseases. Dr. Martin R. Farlow, MD, Professor Emeritus in the Department of Neurology at Indiana University and co-director of the Alzheimer's Disease Center at Indiana University, will serve as Chairperson of the SAB.  Dr. Farlow has authored numerous peer reviewed scientific publications and was lead investigator of the trial showing the first time memantine, when added to donepezil in combination, demonstrated a statistically significant benefit as compared to donepezil alone.

  • PR Newswire8 months ago

    Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting

    NEW YORK, July 2, 2018 /PRNewswire/ -- Neurotrope Inc. (NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), is announcing  the acceptance of a presentation at the Alzheimer's Association International Conference 2018 (AAIC) being held in Chicago, from July 22-26, 2018. "The primary mechanisms of action (MOAs) of bryostatin, Neurotrope's lead compound to treat Alzheimer's disease (AD) neurodegeneration, are synaptogenesis and anti-apoptosis:  the generation of new, mature synaptic connections and the prevention of neuronal death.

  • PR Newswire10 months ago

    Neurotrope, In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimer's Patients

    NEW YORK, May 7, 2018 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), is announcing that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary (the "Company"), has completed the study design for its confirmatory Phase 2 clinical trial in moderate to severe Alzheimer's disease.  The study was designed in consultation with a team of experts in the AD field who are highlighted below. This follow-on confirmatory clinical study will include 100 patients with moderate to severe  AD (defined as a Mini Mental State Exam 2 (MMSE-2) of 4-15).  The primary efficacy endpoint is defined as the change in the SIB score between the baseline and the average of weeks 13 and 15.  Patients will be randomized 1:1 Bryostatin-1 20ug vs. placebo.  Patients on memantine, an NMDA receptor antagonist, will be excluded unless they have been off memantine for 30 days for the reason explained below by Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope.

  • Benzinga11 months ago

    Neurotrope Alzheimer's Candidate Could Generate Revenue Beginning In 2024, Analyst Says

    Alzheimer's drug research has a high failure rate, and symptoms of the disease start appearing long after amyloid plaques — which are responsible for interruption of cell-to-cell signal transfer — deposit ...

  • PR Newswirelast year

    Neurotrope to Present at the Cowen and Company 38th Annual Health Care Conference

    NEW YORK, Feb. 28, 2018 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Daniel Alkon, MD, President and Chief Scientific Officer of Neurotrope, will present at the Cowen and Company 38th Annual Health Care Conference to be held at the Boston Marriott Copley Place, from March 12th - 14th, 2018.  The Corporate presentation is scheduled for Monday, March 12th at 4:50 PM. Neurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases. The Company's world-class science offers the potential to realize a paradigm shift to overcome one of today's most challenging clinical problems — finding a way to slow or even prevent the progression of AD.